BioGrade · expert reasoning data for biopharma agentsEnvironmentsBenchmarkCompare modelsData flywheelThesis
← Adverse-Event Coding & Causality
Clinical / Pharmacovigilance · Drug-safety physician (PV)

Adverse-Event Coding & Causality — agent trajectory for expert review

claude-opus-4-8 · 2026-06-06T09:15:03.335347+00:00 · 6 tool calls · 26.6s · 7631 tokens
run id: ae_causality_20260606_021404_02_for-case-icsr-002-a-patient-on-a-pd-1-checkpoint

Query

For case ICSR-002 (a patient on a PD-1 checkpoint inhibitor), extract and code the adverse events to MedDRA PT/SOC, determine ICH E2A seriousness, and give a WHO-UMC causality assessment for each.

Trajectory

Agent · turn 1

I'll work through this case systematically. Let me start by pulling the case details and the relevant drug label.

⚙ calls get_case(case_id=ICSR-002)
⚙ calls get_drug_label(drug_class=PD-1/PD-L1 checkpoint inhibitor (mAb))
↳ get_case result
show data
{
  "case_id": "ICSR-002",
  "study_drug": "Pembrolizumab",
  "drug_class": "PD-1/PD-L1 checkpoint inhibitor (mAb)",
  "patient": {
    "age": 71,
    "sex": "F",
    "comorbidities": [
      "metastatic NSCLC",
      "never-smoker"
    ],
    "concomitant_meds": [
      "levothyroxine",
      "amlodipine"
    ]
  },
  "narrative": "71-year-old woman on a PD-1 checkpoint inhibitor for NSCLC presented in cycle 5 (approximately 3 months into therapy) with progressive shortness of breath and a dry cough over two weeks, with low oxygen saturation (90% on room air). CT showed bilateral ground-glass opacities. Infectious workup including respiratory viral panel was negative. She was diagnosed with immune-related pneumonitis, admitted, the checkpoint inhibitor was withheld and high-dose corticosteroids were started, with gradual improvement. The drug was permanently discontinued.",
  "events": [
    "shortness of breath with low oxygen (pneumonitis)",
    "dry cough"
  ]
}
↳ get_drug_label result
show data
{
  "drug_class": "PD-1/PD-L1 checkpoint inhibitor (mAb)",
  "examples": [
    "Pembrolizumab",
    "Nivolumab",
    "Atezolizumab"
  ],
  "labeled": [
    "Pneumonitis",
    "Colitis",
    "Diarrhoea",
    "Hypothyroidism",
    "Rash",
    "Pruritus",
    "Fatigue",
    "Alanine aminotransferase increased"
  ],
  "boxed_warning": "Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies).",
  "note": "Immune-related AEs are labeled class effects; onset is typically weeks to months into therapy and is often steroid-responsive (positive dechallenge)."
}
Agent · turn 2

Now let me code the events to MedDRA. The narrative contains distinct events: pneumonitis (with associated hypoxia/dyspnea) and dry cough. Let me look these up.

⚙ calls meddra_lookup(term=pneumonitis)
⚙ calls meddra_lookup(term=shortness of breath)
⚙ calls meddra_lookup(term=low oxygen saturation)
⚙ calls meddra_lookup(term=dry cough)
↳ meddra_lookup result
show data
{
  "query": "pneumonitis",
  "count": 1,
  "matches": [
    {
      "pt": "Pneumonitis",
      "soc": "Respiratory, thoracic and mediastinal disorders",
      "synonyms": [
        "lung inflammation",
        "interstitial lung disease",
        "ild",
        "immune pneumonitis",
        "inflammation of the lungs"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "shortness of breath",
  "count": 1,
  "matches": [
    {
      "pt": "Dyspnoea",
      "soc": "Respiratory, thoracic and mediastinal disorders",
      "synonyms": [
        "shortness of breath",
        "breathlessness",
        "dyspnea",
        "sob",
        "difficulty breathing"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "low oxygen saturation",
  "count": 1,
  "matches": [
    {
      "pt": "Hypoxia",
      "soc": "Respiratory, thoracic and mediastinal disorders",
      "synonyms": [
        "low oxygen",
        "desaturation",
        "low oxygen saturation"
      ]
    }
  ]
}
↳ meddra_lookup result
show data
{
  "query": "dry cough",
  "count": 1,
  "matches": [
    {
      "pt": "Cough",
      "soc": "Respiratory, thoracic and mediastinal disorders",
      "synonyms": [
        "coughing",
        "dry cough"
      ]
    }
  ]
}
Agent · turn 3

I now have everything needed. Here is the full assessment.

ICSR-002 — Adverse Event Assessment

Study drug: Pembrolizumab (PD-1/PD-L1 checkpoint inhibitor, mAb)
Patient: 71F, metastatic NSCLC (never-smoker); concomitant levothyroxine, amlodipine
Clinical course: Cycle 5 (~3 months in) → progressive dyspnea + dry cough over 2 weeks, SpO₂ 90% RA, bilateral ground-glass opacities on CT, infectious workup negative → diagnosed immune-related pneumonitis → admitted, drug withheld, high-dose corticosteroids, gradual improvement, drug permanently discontinued.

Event coding (MedDRA PT / SOC)

The clinical picture is one diagnosed entity — immune-related pneumonitis — with dyspnea and hypoxia as its presenting features, plus a dry cough. I've coded the diagnosis as the primary PT and listed the manifestations separately (per ICH coding convention, code the diagnosis when established rather than each sign individually; symptoms are shown for completeness).

Reported term MedDRA PT SOC
Immune-related pneumonitis (primary diagnosis) Pneumonitis Respiratory, thoracic and mediastinal disorders
Shortness of breath Dyspnoea Respiratory, thoracic and mediastinal disorders
Low oxygen saturation (90% RA) Hypoxia Respiratory, thoracic and mediastinal disorders
Dry cough Cough Respiratory, thoracic and mediastinal disorders

Seriousness (ICH E2A)

Event Serious? E2A criterion
Pneumonitis YES — Serious Caused hospitalization (admitted); also medically significant (hypoxia + high-dose steroids + permanent drug discontinuation; potentially life-threatening if untreated)
Dyspnoea Serious (as part of the hospitalizing event) Contributed to hospitalization / medically significant manifestation of pneumonitis
Hypoxia Serious (as part of the hospitalizing event) Medically significant; component of the serious pneumonitis
Cough Non-serious No E2A criterion met on its own

Note: Dyspnoea, hypoxia and cough are manifestations of the single serious pneumonitis event; the case overall is a serious ICSR (hospitalization).

WHO-UMC causality (drug = pembrolizumab)

Pneumonitis — Probable/Likely
- Temporal plausibility: onset ~3 months into therapy — consistent with the labeled "weeks to months" onset of immune-related AEs. ✓
- Labeled/known reaction: Pneumonitis is a labeled class effect and appears in the boxed warning for immune-mediated reactions. ✓
- Positive dechallenge: improved after drug withheld + corticosteroids. ✓
- Alternative causes reasonably excluded: infectious workup (incl. viral panel) negative; bilateral ground-glass + steroid response argues against infection or progression. ✓
- Rechallenge: none (permanently discontinued) — which is why this is Probable rather than Certain, since "Certain" in WHO-UMC typically requires a satisfactory rechallenge where applicable.

Dyspnoea / Hypoxia — Probable/Likely (assessed as manifestations of the drug-related pneumonitis; same reasoning as above).

Cough — Possible
- Compatible timing and consistent with the pneumonitis presentation, but cough is non-specific (could reflect underlying NSCLC or other causes) and dechallenge data are not isolated for this symptom. Best treated as a symptom of the pneumonitis; if reported as a standalone PT, Possible is the conservative call.

Summary

Caveat: Coding reflects the MedDRA teaching dictionary returns; final case coding should follow your sponsor's convention on coding diagnosis vs. component signs/symptoms.

Final output

I now have everything needed. Here is the full assessment.

ICSR-002 — Adverse Event Assessment

Study drug: Pembrolizumab (PD-1/PD-L1 checkpoint inhibitor, mAb)
Patient: 71F, metastatic NSCLC (never-smoker); concomitant levothyroxine, amlodipine
Clinical course: Cycle 5 (~3 months in) → progressive dyspnea + dry cough over 2 weeks, SpO₂ 90% RA, bilateral ground-glass opacities on CT, infectious workup negative → diagnosed immune-related pneumonitis → admitted, drug withheld, high-dose corticosteroids, gradual improvement, drug permanently discontinued.

Event coding (MedDRA PT / SOC)

The clinical picture is one diagnosed entity — immune-related pneumonitis — with dyspnea and hypoxia as its presenting features, plus a dry cough. I've coded the diagnosis as the primary PT and listed the manifestations separately (per ICH coding convention, code the diagnosis when established rather than each sign individually; symptoms are shown for completeness).

Reported term MedDRA PT SOC
Immune-related pneumonitis (primary diagnosis) Pneumonitis Respiratory, thoracic and mediastinal disorders
Shortness of breath Dyspnoea Respiratory, thoracic and mediastinal disorders
Low oxygen saturation (90% RA) Hypoxia Respiratory, thoracic and mediastinal disorders
Dry cough Cough Respiratory, thoracic and mediastinal disorders

Seriousness (ICH E2A)

Event Serious? E2A criterion
Pneumonitis YES — Serious Caused hospitalization (admitted); also medically significant (hypoxia + high-dose steroids + permanent drug discontinuation; potentially life-threatening if untreated)
Dyspnoea Serious (as part of the hospitalizing event) Contributed to hospitalization / medically significant manifestation of pneumonitis
Hypoxia Serious (as part of the hospitalizing event) Medically significant; component of the serious pneumonitis
Cough Non-serious No E2A criterion met on its own

Note: Dyspnoea, hypoxia and cough are manifestations of the single serious pneumonitis event; the case overall is a serious ICSR (hospitalization).

WHO-UMC causality (drug = pembrolizumab)

Pneumonitis — Probable/Likely
- Temporal plausibility: onset ~3 months into therapy — consistent with the labeled "weeks to months" onset of immune-related AEs. ✓
- Labeled/known reaction: Pneumonitis is a labeled class effect and appears in the boxed warning for immune-mediated reactions. ✓
- Positive dechallenge: improved after drug withheld + corticosteroids. ✓
- Alternative causes reasonably excluded: infectious workup (incl. viral panel) negative; bilateral ground-glass + steroid response argues against infection or progression. ✓
- Rechallenge: none (permanently discontinued) — which is why this is Probable rather than Certain, since "Certain" in WHO-UMC typically requires a satisfactory rechallenge where applicable.

Dyspnoea / Hypoxia — Probable/Likely (assessed as manifestations of the drug-related pneumonitis; same reasoning as above).

Cough — Possible
- Compatible timing and consistent with the pneumonitis presentation, but cough is non-specific (could reflect underlying NSCLC or other causes) and dechallenge data are not isolated for this symptom. Best treated as a symptom of the pneumonitis; if reported as a standalone PT, Possible is the conservative call.

Summary

Caveat: Coding reflects the MedDRA teaching dictionary returns; final case coding should follow your sponsor's convention on coding diagnosis vs. component signs/symptoms.

Reference answer key (deterministic) — open after grading

Deterministic reference key for ICSR-002 (Pembrolizumab). Causality categories follow WHO-UMC; where the narrative supports more than one defensible category the rationale says so. A strong analyst recovers all events, the correct PT/SOC from the dictionary, the right seriousness criterion, and well-reasoned causality grounded in temporality, dechallenge/rechallenge, alternative etiology, and the drug label.

Event (as narrated)Expected PTExpected SOCSeriousness (ICH E2A)Causality (WHO-UMC) + rationale
shortness of breath with low oxygen (pneumonitis)PneumonitisRespiratory, thoracic and mediastinal disordersSerious — Hospitalization (and medically important; potentially life-threatening)Probable — Onset ~3 months into checkpoint-inhibitor therapy fits the known immune-related pneumonitis time course, pneumonitis is a labeled class effect, infectious causes excluded (no plausible alternative), positive dechallenge with steroids and drug discontinuation. No rechallenge.
dry coughCoughRespiratory, thoracic and mediastinal disordersNon-serious — Does not meet a seriousness criterion (symptom of the pneumonitis)Possible — Most likely a symptom of the pneumonitis; cough alone is non-specific with many alternative causes, so coded/assessed conservatively.
OVERALL CASE——Serious — Hospitalization (immune-related pneumonitis)Case-level ICH-E2A determination

Expert grading

Event extraction completeness 1 (poor) 5 (excellent)
5: Identifies every reportable adverse event in the narrative — including a serious event that is unrelated to the drug and secondary/lab events — without lumping distinct events or inventing ones.
1: Misses reportable events (e.g. overlooks the neutropenia behind a febrile-neutropenia admission, or drops the unrelated fracture), or merges separate events into one.
MedDRA coding accuracy 1 (poor) 5 (excellent)
5: Maps each lay event to the correct Preferred Term and its System Organ Class using the dictionary lookup (e.g. 'low white count' -> Neutropenia / Blood and lymphatic system disorders; 'shortness of breath with infiltrates' -> Pneumonitis / Respiratory). PT and SOC are consistent with the dictionary, not guessed from memory.
1: Wrong PT or mismatched SOC, codes to a symptom when a diagnosis PT exists (or vice versa), or fabricates a code never returned by meddra_lookup.
Seriousness determination (ICH E2A) 1 (poor) 5 (excellent)
5: Correctly classifies each event as serious/non-serious and names the right ICH E2A criterion (death, life-threatening, hospitalization, disability, congenital anomaly, medically important) — e.g. flags the hospitalized CRS/pneumonitis/febrile-neutropenia events as serious and the asymptomatic resolved lab abnormality as non-serious.
1: Calls a clearly serious (hospitalized/life-threatening) event non-serious or vice versa, or cites the wrong/no criterion, or conflates severity grade with seriousness.
Causality assessment quality (WHO-UMC) 1 (poor) 5 (excellent)
5: Assigns a defensible WHO-UMC category with sound reasoning: weighs temporality (onset vs dosing), dechallenge/rechallenge, alternative etiologies (confounding meds, comorbidity, trauma), and whether the event is labeled — e.g. probable/certain for step-up-dose CRS, unlikely for the antibiotic-confounded transaminitis, unrelated for the traumatic fracture.
1: Reflexively blames or exonerates the drug, ignores a strong alternative etiology or the temporal mismatch, conflates seriousness with causality, or misuses the WHO-UMC categories.
Evidence faithfulness 1 (poor) 5 (excellent)
5: Grounds every PT/SOC in an actual meddra_lookup result and every causality factor in the narrative or the drug label; no invented events, codes, lab values, or label claims; states uncertainty where the narrative is genuinely ambiguous.
1: Invents events or MedDRA codes, asserts label content not returned by get_drug_label, or contradicts the narrative (wrong timing, fabricated dechallenge).
Overall verdict
Your name / ID